Apurba Ganguly

Dr. Apurba Ganguly


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Open access
AGApurba Ganguly
Apurba Ganguly
Background: C-reactive protein (CRP), creatine kinase-muscle (CK-MM) and aldolase A (AldoA) levels are predicted to be realistic biomarkers of osteoarthritic disorders (OADs). The objective of the study was to evaluate the levels of CRP, CK-MM, and AldoA and determine their correlations with risk factors such as inflammation, muscle degeneration, and skeletal muscle damage for OADs. Methods: Baseline data from 297 patients, average aged 60.17 +/- 7.19 years, suffering with OADs for 5.75 +/- 1.32 years and 315 participants, average aged 58.96 +/- 8.63 years, without OADs were collected in this cross-sectional study. Separate analyses were performed for the participants with and without OAD symptoms confirming with X-ray or MRI. Blood CRP, CK-MM, and AldoA levels were estimated. The receiver operating characteristic (ROC) curves, their respective 95% confidence intervals (CIs), and significance values were compared between participants with and without OADs to identify the risk factors for OADs in relation to biomarkers. Results: In patients with OADs, who exhibited degenerative changes on musculoskeletal joints and risk factors based on the elevated levels of CRP, CK-MM, and AldoA having their mean +/- SD values, 7.22 +/- 6.09 mg/L,135.2 +/- 78.56 U/L and 8.09 +/- 2.15 U/L, respectively. Their respective values of areas under the curves (AUC) of ROC curves were 0.76, 0.68 and 0.91 respectively, of which all exhibited highly significant differences (p<0.0001) compared with the control subjects. Conclusion: It is concluded from the results that the elevated levels of studied biomarkers represent the predictive above-mentioned risk factors during OADs; therefore, monitoring CRP, CK-MM and AldoA levels may be an effective diagnostic method confirming with radiological imaging.

22 November 2019 in Medical Sciences
Verified
Journal Article
Open access
PDF file
AGApurba Ganguly
Apurba Ganguly
The aim of this study was to use Jumpstart Nutrition® bone supplementing combination with vitamin-K2 and coenzyme-Q10 characterized by an innovative delivery system that improves bioavailability of calcium-to-phosphorus ratio (CPR) and parathyroid hormone (PTH) in the management of osteoarthritis (OA). This eight-week registry included 108 patients treated for symptomatic OA confirmed with radiological images. On top of that, 63 patients used Jumpstart Nutrition® supplement, mainly prepared with calcium, phosphorus, coenzyme-Q10, vitamin-K2, vitamin-D2, vitamin-C, folic acid, curcumin and boswellic acids. Rescue medication was also recommended. Patients’ pain and functional capacity through outcome measures—knee-injury osteoarthritis outcome scale (KOOS) and Karnofsky performance scale (KPS), biomarkers such as levels of CPR, PTH and 25-hydroxy-vitamin-D were evaluated for the groups with and without supplement using appropriate kits. After eight weeks, the levels of CPR and PTH were all significantly improved (p < 0.001), fewer subjects had to use rescue medication (p < 0.05) and variation of pain and functional capacity under KOOS and KPS (p < 0.05) of the patients in the supplement group compared to controls. This registry study indicates that Jumpstart Nutrition® can be used safely for effective management of OA patients for the amelioration of CPR, PTH and functional activities confirmed with biomarkers and radiological images correlated with the Kellgren-Lawrance scale.

1 January 2023
Verified
Journal Article
Open access
AGApurba Ganguly
Apurba Ganguly
BSBanerjee Sudip
Banerjee Sudip
Background: This study aimed to investigate the efficacy of Jumpstart Nutrition (R) dietary supplement (JNDS) for enhancing the skeletal muscle metabolism and function of older adults with knee osteoarthritis (KOA) by evaluating the biomarkers of aberrant levels of serum tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10), C-reactive protein (CRP), creatine kinase-muscle (CK-MM), and aldolase-A (Aldo-A). Methods: This twelve-week registry included 54 patients treated with JNDS mainly comprised of calcium, phosphorus, vitamin-K-2, coenzyme-Q(10), boswellic acid, and curcumin mixed with soy and whey protein (experimental group) and 51 patients treated with symptomatic slow-acting drugs for osteoarthritis (SYSADOA) (control group) for KOA confirmed with radiological images. At week 0 and week 12 for both the groups evaluated, the non-fasting serum levels of TNF-alpha, IL-10, CRP, CK-MM, and Aldo-A by using appropriate kits. Results: At week-twelve, the respective values of area under the ROC curves of the studied biomarkers for pooled experimental cohorts were 0.928, 0.907, 0.908, 0.927, and 0.988 having the significance of accuracy (R-square):66.28%, 47.25%, 70.39%, 65.13%, and 68.00%, indicating a satisfactory treatment policy, their mean +/- SD, and risk ratio, all exhibited highly significant differences (p= 2 and >= 3 from >= 4 as per the Kellgren-Lawrence scale compared to the control. Fewer patients had to use emergency medications (p<0.05). Conclusions: Results suggest that JNDS may be effectively used to strengthen the skeletal muscle metabolism and function of elderly patients with KOA confirmed with the stabilization of studied biomarkers as an alternative to the treatment of SYSAD correlated with ROC curves and the Kellgren-Lawrence scale.

12 June 2019 in Medical Sciences
Verified
Journal Article
Open access
PDF file
AGApurba Ganguly
Apurba Ganguly
The aim of this study was to determine a cost-effective diagnostic method for lumbar herniated disc with knee osteoarthritis (LHD-KOA) based on aberrant outcome measures, levels of biomarkers, and examination of the lower-extremity. Data were separately analyzed for each cohort suffering with LHD-KOA (n = 108; 59.82 ± 7.15 years) and without LHD-KOA (n = 108; 58.81 ± 7.61 years), and findings were confirmed with radiological images. The aberrant-leg-features (bilateral: knee gaps between the short head of biceps femoris and the surface of the bed, diameters of calves and thighs, angles of straight leg raising, knee-flexion and -extension in a supine position) and biochemical parameters (Interleukin-10, Tumor necrosis factor-alpha, C-reactive protein, creatine kinase-muscle, and Aldolase-A), and outcome measures, Western Ontario and McMaster Universities osteoarthritis index (WOMAC), knee-injury osteoarthritis outcomes scale (KOOS), Oswestry disability index (ODI), and body mass index (BMI)for participants with and without LHD-KOA were evaluated with appropriate techniques. All the subjects underwent standardized physical examination and completed a questionnaire. The risk ratios and mean ± standard deviations of biomarkers, anatomical features, and outcome measures of the experimental subjects were highly significant compared to controls (p < 0.0001). Results suggest that monitoring the studied aberrant outcome measures, biomarkers, and lower-anatomical features may be a cost-effective diagnostic tool for LHD-KOA. Further research is recommended for an alternative treatment protocol for LHD-KOA.

1 January 2024
Verified
Journal Article
Open access
AGApurba Ganguly
Apurba Ganguly
Background: Osteoarthritis (OA) is characterized by cartilage and synovial inflammation as well as anomalous lower extremity leading to joint pain, and impairment in lifestyle and epidemic of obesity. This study aimed to use the Jumpstart Nutrition (R) supplement (JNS) for achieving symmetry of aberrant lower extremity and improving the outcome measures in the management of OA.Methods: This week-twelve registry included 108 patients treated with JNS mainly comprised of calcium, phosphorus, magnesium, vitamin-K-2, coenzyme-Q(10), vitamin-C, boswellic acids, and curcumin mixed with soy and whey proteins (experimental group) and 72 were treated with symptomatic slow-acting drugs (control group) for chronic OA confirmed with radiological images. The outcome measures (Visual analogue scale, Western Ontario and McMaster Universities Osteoarthritis Index, Knee-injury Osteoarthritis Outcomes Scale, and Body mass index), and anomalous lower extremity included bilateral: knee gaps between biceps femoris-short head and surface of the bed, diameters of muscles at the calf, the thigh, 4cm above and below the patella, angles of straight leg raising, knee- flexion and-extension in supine were evaluated with appropriate protocol at week-0 and at week-12 for both the groups.Results: After week-12, risk ratios of studied lower extremity, and mean +/- standard deviation of all outcome measures were significantly improved (p= 2 in experimental group compared to control.Conclusions: This registry study indicates that JNS can be used to achieve symmetry of studied lower extremity and to improve the outcome measures safely as an effective management of OA patients confirmed with radiological images correlated with KLS.

30 September 2024 in International Journal of Research in Medical Sciences
Verified
Journal Article
Open access
PDF file
AGApurba Ganguly
Apurba Ganguly
SBSudip K. Banerjee
Sudip K. Banerjee
VVVidya Sagar Gubby Venkatesh
Vidya Sagar Gubby Venkatesh
DSDinesh K. Singal
Dinesh K. Singal
AGAnondeep Ganguly
Anondeep Ganguly
Background: This study investigates Venifixe®, a cost-effective phyto-vanoactive infused oil, as an alternative treatment for epidermal and venous ailments (EVA). Venifixe® combines venoactive phyto-complexes, hydrophilic botanical extracts, essential oils, carrier oils, and epidermal care components. The study strives to offer a non-invasive and potentially more effective alternative to conventional treatments, aiming to improve or prevent various EVAs and enhance patients' quality of life. Despite the array of existing treatments, there remains a need for formulations offering enhanced efficacy, reduced invasiveness, and broader applicability. Methods: Over twelve weeks, 250 participants (average age: 59.91±7.25 years), diagnosed with varicosities via ultrasonography, were included. Participants were divided into two groups: 142 received standard management (SM) for symptomatic EVA, and 108 received Venifixe® treatment. Both groups were assessed for EVA-related symptoms (pain, itchiness, restlessness, swelling/edema, heaviness, and leg cramps) and Venous Clinical Severity Score (VCSS) based on CEAP classification pre-and post-treatment. Results: At twelve weeks, the Venifixe® group demonstrated a VCSS ROC curve (AUC=0.905, 95% CI: 0.89-0.92, p<0.0001), with 93.68% sensitivity, 61.11% specificity, and 75.43% accuracy, indicating favorable treatment outcomes. Significant reductions in VCSS risk ratios and associated symptom prevalence (p<0.0001) led to an improved NHS gradation scale from level 3 to level 2 compared to the SM group. Conclusions: Venifixe®'s topical application provides a more effective phytotherapeutic approach for EVA compared to standard management, offering symptom relief and enhancing quality of life. These results, supported by ROC curves and NHS gradation improvements, warrant further clinical investigation.